René S. Kahn, MD, PhD, is the Chair of Psychiatry at Icahn School of Medicine at Mount Sinai, and has spent his career working in psychiatry after training in both psychiatry and neurology. Dr. Kahn’s research focuses on schizophrenia, mainly working in brain imaging and clinical trials comparing various medications in patients with schizophrenia.
Mount Sinai announced in September 2024 that Kahn would be 1 of 3 investigators leading a new study, joining Cheryl Corcoran, MD, and Guillermo Cecchi, PhD. The Phenotypes Reimagined to Define Clinical Treatment and Outcome Research (PREDiCTOR) study aims to leverage advances in artificial intelligence (AI) to address the lack of objective measures in psychiatry. A press release from Mount Sinai said the study will be conducted in collaboration with researchers from Harvard, Johns Hopkins, Columbia, and Carnegie Mellon universities, as well as Deliberate AI. Dr. Kahn sat down with Psychiatric Times to discuss the study and the potential AI has for future clinical use.
